[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614227":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":37,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":10,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Indocyanine green-Ferritin (ICG-FTn)",null,"Freshly resected gastric cancer specimens were perfused ex vivo via the gastric artery with the targeted probe FTn-ICG solution for about 10 minutes, followed by fluorescence imaging using a DPM system. The results were analyzed to identify tumor regions and delineate tumor margins.",[13],"Diagnostic Test: Diagnostic Test: ICG-FTn perfusion solution",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Diagnostic Test: ICG-FTn perfusion solution","The freshly resected gastric cancer specimens were arterially perfused with ICG-FTn solution and underwent fluorescence imaging.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Yanfeng Hu","CONTACT","+86 13632494551","yfenghu@qq.com",[27],{"facility":5,"status":10,"city":28,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Guangzhou","China","CN",{"type":32,"coordinates":33},"Point",[34,35],113.25,23.11667,{"lat":35,"lon":34},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100614227","novel-humanized-ferritin-based-nir-fluorescent-molecular-probe-for-identifying-tumor-margins-in-gastric-tissue-100614227",false,"NCT07276854","Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue","Study of a Novel Near-Infrared (NIR) Fluorescent Molecular Probe Based on Humanized Ferritin for the Identification of Benign and Malignant Margins in Gastric Tissue","Inclusion Criteria:\n\n* Pathologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma eligible for radical resection, with histologically verified predominant adenocarcinoma component; Age ≥ 18 years; No gender restriction ; Voluntary participation with written informed consent.\n\nExclusion Criteria:\n\n* Patients who have received neoadjuvant therapy; Patients deemed ineligible for participation by the investigator's assessment.","ALL","18 Years",{"count":49,"type":50},32,"ESTIMATED","OBSERVATIONAL","Radical surgery remains the primary treatment for gastric cancer, but intraoperative tumor margin assessment relies on surgeons' visual inspection, limiting accuracy. There is thus an urgent clinical need for real-time visualisation of tumour margins.\n\nIn recent years, near-infrared (NIR) fluorescence imaging has emerged as a critical tool for precision tumor resection. However, existing probes like indocyanine green (ICG) lack tumor-targeting specificity. Ferritin (FTn), with its unique nanocage structure, excellent biosafety, and well-defined in vivo behavior, presents an attractive platform for targeted molecular probes.\n\nYet, translational challenges persist, including animal model limitations and clinical validation bottlenecks. To address this, our study employs freshly resected human gastric tissue in an ex vivo perfusion system, simulating the circulatory dynamics of the humanized ferritin-based probe FTn-ICG in vivo. Using a prospective clinical sample cohort, we aim to validate its diagnostic efficacy in delineating gastric cancer margins, ultimately overcoming the critical barrier of precise tumor boundary identification.",[54,55],"Gastric Cancer","Molecular Imaging","NOT_YET_RECRUITING","2025-11-30",{"date":59,"type":60},"2025-12-11","ACTUAL",{"date":62,"type":50},"2025-12-30",{"date":64,"type":50},"2026-08-01",{"name":5,"class":6},1]